Hypertension as predictive factor for bevacizumab‑containing first‑line therapy in metastatic breast and colorectal cancer in BRECOL (GEICAM/2011‑04) study

• Álvaro Rodríguez Lescure ^[1] ; Javier Gallego ^[1] ; Raúl Márquez ^[6] ; Lourdes Calvo ^[6] ; Pedro Sánchez Rovira ^[6] ; Antonio Antón ^[6] ; José Ignacio Chacón ^[6] ; Jose Juan Ponce ^[6] ; María José Escudero ^[6] ; Rosalía Caballero ^[6] ; Susana Bezares ^[6] ; Pilar Garcia Alfonso ^[2] ; Bartomeu Massuti ^[7] ; Sara Encinas ^[8] ; María Rosario Dueñas ^[3] ; Vicente Alonso ^[4] ; Eva Ciruelos ^[9] ; Luis Robles ^[9] ; Ana Santaballa ^[10] ; Jorge Aparicio ^[10] ; Manuel Valladares Ayerbes ^[5] ; Juan de la Haba Rodriguez ^[11]
  1. [1] Hospital General Universitario de Elche

     Hospital General Universitario de Elche

     Elche, España

     
  2. [2] Hospital General Universitario Gregorio Marañón

     Hospital General Universitario Gregorio Marañón

     Madrid, España

     
  3. [3] Hospital Universitario de Jaén

     Hospital Universitario de Jaén

     Jaén, España

     
  4. [4] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  5. [5] Hospital Universitario Virgen del Rocío

     Hospital Universitario Virgen del Rocío

     Sevilla, España

     
  6. [6] GEICAM Spanish Breast Cancer Group, Madrid, Spain
  7. [7] Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Hospital General Universitario Dr. Balmis, Alicante, Spain
  8. [8] MD Anderson Cancer Center Madrid, Madrid, Spain
  9. [9] Hospital Universitario, 12 de Octubre, Madrid, Spain
  10. [10] Hospital Universitario y Politécnico La Fe, Valencia, Spain
  11. [11] Instituto Maimónides de Investigación Biomédica (IMIBIC), Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 8, 2024, págs. 1896-1907
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background Retrospective data suggest an association between bevacizumab efficacy and the incidence of arterial hypertension (AHT). Additionally, epigenetic mechanisms have been related to AHT.

    Methods This prospective observational study conducted by GEICAM Spanish Breast Cancer Research Group included metastatic breast (MBC) or colorectal (mCRC) cancer patients treated with bevacizumab-containing chemotherapy as first-line treatment. Blood pressure (BP) levels were measured (conventional and 24-h Holter monitoring) at baseline and up to cycle 3. Primary endpoint assessed BP levels increase as predictive factor for progression-free survival (PFS). Germline DNA methylation profile was explored in pre-treatment blood samples; principal component analysis was used to define an epigenetic predictive score for increased BP levels.

    Results From Oct-2012 to Jul-2016, 143 (78 MBC and 65 mCRC) patients were included. The incidence of AHT according to guidelines was neither predictive of PFS nor of best overall tumor response (BOR). No statistically significant association was observed with systolic BP nor diastolic BP increment for PFS or BOR. Grade 3 and 4 adverse events were observed in 37 and 5% of patients, respectively. We identified 27 sites which baseline methylation status was significantly associated to BP levels increase secondary to bevacizumab-containing chemotherapy.

    Conclusions Neither the frequency of AHT nor the increase of BP levels were predictive of efficacy in MBC and mCRC patients treated with bevacizumab-containing chemotherapy.

    Clinical trial registry ClinicalTrials.gov Identifier: NCT01733628.